Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02320721




Registration number
NCT02320721
Ethics application status
Date submitted
16/12/2014
Date registered
19/12/2014
Date last updated
21/04/2020

Titles & IDs
Public title
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Scientific title
A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin
Secondary ID [1] 0 0
2014-002399-10
Secondary ID [2] 0 0
EFC13799
Universal Trial Number (UTN)
Trial acronym
SENIOR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes Mellitus 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Insulin Glargine (HOE901 - U300)
Treatment: Drugs - Insulin Glargine (HOE901 - U100)
Treatment: Drugs - Background therapy

Experimental: HOE901-U300 - HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.

Active comparator: Lantus - Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.


Treatment: Drugs: Insulin Glargine (HOE901 - U300)
Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

Treatment: Drugs: Insulin Glargine (HOE901 - U100)
Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

Treatment: Drugs: Background therapy
Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in HbA1c From Baseline to Week 26
Timepoint [1] 0 0
Baseline, Week 26
Secondary outcome [1] 0 0
Percentage of Participants With At Least One Severe and/ or Confirmed (=3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period
Timepoint [1] 0 0
Baseline up to Week 26
Secondary outcome [2] 0 0
Percentage of Participants With At Least One Severe and/ or Confirmed (=3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period
Timepoint [2] 0 0
Baseline up to Week 26
Secondary outcome [3] 0 0
Percentage of Participants With At Least One Severe and/ or Confirmed (=3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period
Timepoint [3] 0 0
Baseline up to Week 26
Secondary outcome [4] 0 0
Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period
Timepoint [4] 0 0
Baseline up to Week 26
Secondary outcome [5] 0 0
Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (=3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period
Timepoint [5] 0 0
Baseline up to Week 26
Secondary outcome [6] 0 0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
Timepoint [6] 0 0
Baseline, Week 26
Secondary outcome [7] 0 0
Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26
Timepoint [7] 0 0
Baseline, Week 26
Secondary outcome [8] 0 0
Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment
Timepoint [8] 0 0
Baseline up to Week 26

Eligibility
Key inclusion criteria
Inclusion criteria:

* Participants =65 years old with type 2 diabetes mellitus, inadequately controlled on antidiabetic regimens either including no insulin, or with basal insulin as their only insulin.
* Signed informed consent.
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* HbA1c at screening visit:

* <7.0% or >10.0% for participants taking basal insulin.
* <7.5% or >11.0% for insulin-naïve participants.
* History of type 2 diabetes mellitus for less than 1 year before screening.
* Participants not on stable basal insulin dose (±10% in the last 8 weeks prior to screening visit).
* Change in dose of antidiabetic treatment or initiation of new glucose-lowering medications in the last 8 weeks prior to screening.
* Chronic (>10 days continuous use in previous 6 months) use of bolus insulin injections, whether given separately or as part of a combination with basal insulin, e.g. premix insulin; For insulin-naïve individuals: current or previous insulin use except for a maximum of 10 consecutive days (e.g. acute illness, surgery) during the last year prior to screening.
* Cognitive disorder and dementia assessed clinically and by Mini-Mental State Examination (MMSE) score <24, or any neurologic disorder that would likely affect the participant's ability to follow the study procedure. The participant would be eligible despite an MMSE score <24 if the investigator determined that the low score reflected educational or cultural background and not dementia as long as the participant was otherwise able to meet the study requirements.
* Participants who had end-stage renal disease (<15 mL/min/1.73m^2, per estimated Glomerular filtration rate (eGFR) measurement by Modification of Diet in Renal Disease (MDRD).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2016
Sample size
Target
Accrual to date
Final
1014
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigational Site Number 036002 - Box Hill
Recruitment hospital [2] 0 0
Investigational Site Number 036004 - Fitzroy
Recruitment hospital [3] 0 0
Investigational Site Number 036001 - Geelong
Recruitment hospital [4] 0 0
Investigational Site Number 036003 - Herston
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3220 - Geelong
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
North Dakota
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Capital Federal
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma De Buenos Aire
Country [28] 0 0
Argentina
State/province [28] 0 0
Mar Del Plata
Country [29] 0 0
Canada
State/province [29] 0 0
Brampton
Country [30] 0 0
Canada
State/province [30] 0 0
Burlington
Country [31] 0 0
Canada
State/province [31] 0 0
Chatham
Country [32] 0 0
Canada
State/province [32] 0 0
Mirabel
Country [33] 0 0
Canada
State/province [33] 0 0
Montreal
Country [34] 0 0
Canada
State/province [34] 0 0
Sainte-Foy
Country [35] 0 0
Canada
State/province [35] 0 0
Thornhill
Country [36] 0 0
Canada
State/province [36] 0 0
Toronto
Country [37] 0 0
Canada
State/province [37] 0 0
Vancouver
Country [38] 0 0
Colombia
State/province [38] 0 0
Armenia
Country [39] 0 0
Colombia
State/province [39] 0 0
Barranquilla
Country [40] 0 0
Colombia
State/province [40] 0 0
Bogota
Country [41] 0 0
Colombia
State/province [41] 0 0
Manizales
Country [42] 0 0
France
State/province [42] 0 0
Lyon
Country [43] 0 0
France
State/province [43] 0 0
Nantes Cedex 01
Country [44] 0 0
France
State/province [44] 0 0
Poitiers Cedex
Country [45] 0 0
Germany
State/province [45] 0 0
Dresden
Country [46] 0 0
Germany
State/province [46] 0 0
Essen
Country [47] 0 0
Germany
State/province [47] 0 0
München
Country [48] 0 0
Germany
State/province [48] 0 0
Potsdam
Country [49] 0 0
Germany
State/province [49] 0 0
Saarlouis
Country [50] 0 0
Hungary
State/province [50] 0 0
Balatonfüred
Country [51] 0 0
Hungary
State/province [51] 0 0
Budapest
Country [52] 0 0
Hungary
State/province [52] 0 0
Csongrád
Country [53] 0 0
Hungary
State/province [53] 0 0
Debrecen
Country [54] 0 0
Hungary
State/province [54] 0 0
Gyula
Country [55] 0 0
Italy
State/province [55] 0 0
Bologna
Country [56] 0 0
Italy
State/province [56] 0 0
Chieti
Country [57] 0 0
Italy
State/province [57] 0 0
Genova
Country [58] 0 0
Italy
State/province [58] 0 0
Milano
Country [59] 0 0
Japan
State/province [59] 0 0
Adachi-Ku
Country [60] 0 0
Japan
State/province [60] 0 0
Atsugi-Shi
Country [61] 0 0
Japan
State/province [61] 0 0
Kamakura-Shi
Country [62] 0 0
Japan
State/province [62] 0 0
Sagamihara-Shi
Country [63] 0 0
Japan
State/province [63] 0 0
Sakado-Shi
Country [64] 0 0
Japan
State/province [64] 0 0
Sapporo-Shi
Country [65] 0 0
Japan
State/province [65] 0 0
Sendai-Shi
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seoul
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Wonju
Country [68] 0 0
Mexico
State/province [68] 0 0
Aguascalientes
Country [69] 0 0
Mexico
State/province [69] 0 0
Cuernavaca
Country [70] 0 0
Mexico
State/province [70] 0 0
Guadalajara
Country [71] 0 0
Mexico
State/province [71] 0 0
Monterrey
Country [72] 0 0
Peru
State/province [72] 0 0
Arequipa
Country [73] 0 0
Peru
State/province [73] 0 0
Ica
Country [74] 0 0
Peru
State/province [74] 0 0
Lima
Country [75] 0 0
Peru
State/province [75] 0 0
Piura
Country [76] 0 0
Poland
State/province [76] 0 0
Lublin
Country [77] 0 0
Poland
State/province [77] 0 0
Szczecin
Country [78] 0 0
Poland
State/province [78] 0 0
Warszawa
Country [79] 0 0
Poland
State/province [79] 0 0
Zabrze
Country [80] 0 0
Romania
State/province [80] 0 0
Bacau
Country [81] 0 0
Romania
State/province [81] 0 0
Bucuresti
Country [82] 0 0
Romania
State/province [82] 0 0
Constanta
Country [83] 0 0
Romania
State/province [83] 0 0
Oradea
Country [84] 0 0
Romania
State/province [84] 0 0
Sibiu
Country [85] 0 0
Romania
State/province [85] 0 0
Targu Mures
Country [86] 0 0
Spain
State/province [86] 0 0
Alzira
Country [87] 0 0
Spain
State/province [87] 0 0
Badalona
Country [88] 0 0
Spain
State/province [88] 0 0
El Ferrol
Country [89] 0 0
Spain
State/province [89] 0 0
La Coruña
Country [90] 0 0
Spain
State/province [90] 0 0
Málaga
Country [91] 0 0
Spain
State/province [91] 0 0
Quart De Poblet
Country [92] 0 0
Spain
State/province [92] 0 0
Sanlúcar De Barrameda
Country [93] 0 0
Spain
State/province [93] 0 0
Sevilla
Country [94] 0 0
Sweden
State/province [94] 0 0
Göteborg
Country [95] 0 0
Sweden
State/province [95] 0 0
Härnösand
Country [96] 0 0
Sweden
State/province [96] 0 0
Rättvik
Country [97] 0 0
Sweden
State/province [97] 0 0
Västra Frölunda
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Belfast
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Bristol
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Redhill
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Rotherham
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary Objective:

To demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c).

Secondary Objectives:

To demonstrate the superiority of H0E901-U300 in comparison with Lantus in:

* Percentage of participants with at least one severe and/or confirmed (by plasma glucose =70mg/dL \[3.9mmol/L\]) hypoglycemia event from 22:00 to 08:59 next morning
* Percentage of participants with at least one nocturnal (from 00:00-05:59) severe and/or confirmed (=70mg/dL \[3.9mmol/L\]) hypoglycemia event
* Percentage of participants with at least one severe and/or confirmed (by plasma glucose =70mg/dL \[3.9mmol/L\]) hypoglycemia event occurring at any time of day
* HbA1c change
Trial website
https://clinicaltrials.gov/study/NCT02320721
Trial related presentations / publications
Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2018 Aug;41(8):1672-1680. doi: 10.2337/dc18-0168. Epub 2018 Jun 12. Erratum In: Diabetes Care. 2019 Aug;42(8):1604. doi: 10.2337/dc19-er08.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02320721